Dr. Juanita Crook does an excellent discussion about the importance of RT dose escalation in prostate cancer, and also the importance of PSA at 3mo post RT for high risk prostate cancer patients - PSS<0.1 much better. #GU20

To quote Prof Sudeep Gupta "We are creating a symphony of modalities to make cancer care available affordable and evidence based throughout the country" Heartfelt gratitude Prof Pramesh Pramesh CS Sir and Prof Jayanta Chakraborty Sir #NCGmeeting2024 #TMH #cnci

"Oligo"-no more! 🇨🇦ARREST phase I out now IJROBP - The Red Journal - Sue Yom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. shorturl.at/gStwt Congrats! 👏👏

PEACE-1 RT is now published online at The Lancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…

Irresponsible statements … Kindly don’t get fooled . 🙏🏽

Such a poor excuse for investigative journalism! Do better, Economic Times Take a principled stance instead of hedging on "middle ground" & "we can be forgiven for distrusting scientific evidence". If you can't be data and evidence driven, you can't call yourself balanced.

⭐️Ph3 PANOVA-3 trial for LAPC is positive⭐️ 👉#TTF ⬆️ OS vs chemo alone👏 👉#radonc NOT used 👉Supports my ongoing single arm ph2 trial of ablative RT + TTF after chemo for LAPC (NCT05679674) - pls share! 🙏 Novocure Let's Win Pancreatic Cancer 💜 PanCAN Lustgarten Foundation businesswire.com/news/home/2024…

🔥NRG GI-007🔥 LA-Esophagus Carcinoma 🔍 dCRT (50.4 Gy/28 fx carbo/taxol) + endoscopically injected oncolytic virus OBP-301 ✅💯 cCR rate❗️ ✅Comparatively favorable AE profile 👏🏽👏🏽 Brilliant work and looking forward to future study!! #GI25 ASCO NRG Oncology

Updates in PCS-9 Trial: metastasis-directed therapy with SOC in oligometastatic mCRPC ASCO #GU25 Addition of MDT SBRT + SOC in oligometastatic CRPC lead to: ✅52% reduction of rPFS with SBRT (4.6 vs 2.3 years) ✅58% reduction in time to next line of therapy in mCRPC (5.1y vs

Management of Biochemical Recurrence after Radiation Therapy for Localized #ProstateCancer: Reirradiation, Brachytherapy and SBRT. Juanita Crook, MD. FRCPC University of British Columbia on Salvage Reirradiation for Radio-Recurrent #ProstateCancer 💡 Salvage Options: ✅ LDR Brachytherapy: 5-yr BCR-free

Our critical review of contemporary radiation therapy for locally advanced #pancreaticcancer is in press IJROBP - The Red Journal 🙌 Jonathan Ashman, MD Krishan Jethwa Jordan Kharofa Eugene J. Koay, MD, PhD Ethan Ludmir MD Eric Miller Marsha Reyngold Dr. Nina Niu Sanford Daniel Chang redjournal.org/article/S0360-…

Can targeted SBRT help men with oligoprogressive #prostatecancer avoid chemotherapy for longer? Priyanka P, Alison Tree 💙 and team from The Royal Marsden NHS Foundation Trust publish results from the Prostate Cancer UK-funded TRAP trial in IJROBP - The Red Journal. Grab a ☕ and read: doi.org/10.1016/j.ijro…

📢Very proud of our recent publications from Miami Cancer Institute Research ...results of SMART ONE, proton RICE categorization, and SBRT for infra-diaphragmatic oligomets with MRgRT...something for everyone, check it out now online at IJROBP - The Red Journal! Michael Chuong

RACE-GB, the first ever phase 3 randomized study showing overall survival improvement from chemotherapy combined with #radiation for gallbladder cancer. Accompanying podcast for context. Podcast: redjournal.org/audio-do/red-j… Article: redjournal.org/article/S0360-…

⚙️ The approach: Tumor biopsy Isolate TILs Test for neoantigen reactivity Use CRISPR-Cas9 to knock out CISH Expand the edited TILs Reinfuse into patient after lymphodepletion + IL-2 support 🧬 A fully personalized, gene-edited immunotherapy!

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

👀 #radonc - ☢️Should we be thinking of timing of #radiotherapy as a factor? Gerry Hanna Drew Moghanaki Henning Willers, MD, FASTRO Søren M Bentzen Ralph Weichselbaum